Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gaush Meditech Ltd. ( (HK:2407) ) has issued an update.
Gaush Meditech Ltd announced that its subsidiary, Gaush Tech, has received a medical device registration certificate in China for its ophthalmic electrophysiological diagnostic system. This system integrates Visual Evoked Potential, Electroretinography, and Electrooculography to provide comprehensive assessments of the visual system. It is non-invasive and aids in the diagnosis and monitoring of various eye diseases, offering significant benefits for both patients and healthcare providers by enabling precise and early-stage diagnosis.
The most recent analyst rating on (HK:2407) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on Gaush Meditech Ltd. stock, see the HK:2407 Stock Forecast page.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd is a company incorporated in the Cayman Islands, focusing on the medical technology industry. It specializes in developing advanced diagnostic systems, particularly in the field of ophthalmology, to enhance the detection and treatment of eye-related conditions.
Average Trading Volume: 137,716
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.33B
Find detailed analytics on 2407 stock on TipRanks’ Stock Analysis page.